Assessing anaphylactic risk? Consider mast cell clonality
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The ability to predict risk for severe anaphylaxis is an important goal for physicians. Bonadonna et al advance this effort with data from a 3-year prospective study that analyzed 44 patients with a serum baseline total tryptase (sBT) level >11.4 ng/mL who were culled from 379 patients with a previous systemic immediate hypersensitivity reaction to a Hymenoptera sting. Their data indicate that the majority of such patients have an underlying clonal mast cell disorder, either systemic mastocytosis or monoclonal mast cell activation syndrome, by assessing the bone marrow for mast cell granulomas, spindle-shaped mast cells, and mast cells expressing surface CD2 or CD25; and the serum for an elevated sBT level. This is the most comprehensive study to date of the relationships among Hymenoptera sting–induced anaphylaxis, sBT levels, and mast cell clonality. The article raises important issues relating to sBT levels and activating mutations in c-kit, which codes for KIT, the receptor for stem cell factor, (which appear to result in a hyperresponsive mast cell phenotype) as biomarkers for anaphylactic risk. Serum baseline total tryptase levels elevated in the setting of a hypotensive or systemic immediate hypersensitivity event—that is, anaphylaxis—have been used as evidence of mast cell degranulation. Persistent elevation in sBT >20 ng/mL has been set as a minor diagnostic criterion for the diagnosis of mastocytosis. Importantly, in this study by Bonadonna et al, a sBT level of >11.4 ng/mL not only identified patients likely to have a clonal mast cell disorder but also those at risk for systemic anaphylaxis. In fact, an odds ratio of 6.2 (95% CI, 3.1-12.4) can be calculated for having had a stage IV anaphylactic reaction if the sBT level was >11.4 ng/mL among the patient group with a systemic reaction to a Hymenoptera sting. A heightened risk for more severe anaphylactic reactions to Hymenoptera stings in those with an elevated sBT has been noted previously. An analogous odds ratio calculation for risk of mast cell clonality in subjects with
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 1×
“(14) This monoclonal mast cell activation syndrome was identified by Bonadonna et al in 9 of the 34 patients with elevated tryptase who had agreed to a bone marrow examination.”
BackgroundSelf-citationDiagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
Schwartz, L. B. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.05.010 · Cited by 477 · cited 1×
“Based on the observations that α/β-protryptases are spontaneously secreted by unstimulated mast cells in culture,(8) and appear to be the principal form of tryptase detected in serum or plasma in both healthy patients and those with systemic mastocytosis when their clinical signs and symptoms are quiescent, levels of…”
BackgroundSelf-citationBonadonna, P., Perbellini, O., Passalacqua, G., Caruso, B., Colarossi, S., Dal Fior, D., Castellani, L., Bonetto, C., Frattini, F., Dama, A., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.11.018 · Cited by 392
Schwartz, L. B., Sakai, K., Bradford, T. R., Ren, S., Zweiman, B., Worobec, A. S., & Metcalfe, D. D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118337 · Cited by 371
Self-citationAkin, C., Scott, L. M., Kocabas, C. N., Kushnir-Sukhov, N., Brittain, E., Noel, P., & Metcalfe, D. D. (2007) · Blood · doi:10.1182/blood-2006-06-028100 · Cited by 240
Self-citationUnderstanding the mechanisms of anaphylaxis
Peavy, R. D., & Metcalfe, D. D. (2008) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0b013e3283036a90 · Cited by 211 · cited 1×
“Further research is needed to determine if mast cell responsiveness is one determinant of the threshold to elicit an allergic reaction and perhaps the subsequent severity of the allergic inflammatory response.(17) A corollary to this line of thought is that inhibiting the tyrosine kinase activity of activating/mutatio…”
BackgroundSelf-citationOmalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
Carter, M. C., Robyn, J. A., Bressler, P. B., Walker, J. C., Shapiro, G. G., & Metcalfe, D. D. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.03.032 · Cited by 172 · cited 1×
“Such approaches might include the use of omalizumab (19) or venom immunotherapy.”
BackgroundSelf-citationSchwartz, L. B., Min, H.-K., Ren, S., Xia, H.-Z., Hu, J., Zhao, W., Moxley, G., & Fukuoka, Y. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.11.5667 · Cited by 120
Self-citation
Cited by
World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis
Simons, F. E. R., Ardusso, L. R. F., Bilò, M. B., El-Gamal, Y. M., Ledford, D. K., Ring, J., Sanchez-Borges, M., Senna, G. E., Sheikh, A., & Thong, B. Y. (2011) · World Allergy Organization Journal · doi:10.1097/wox.0b013e318211496c · Cited by 973
Valent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Self-citationWorld Allergy Organization anaphylaxis guidelines: Summary
Simons, F. E. R., Ardusso, L. R. F., Bilò, M. B., El-Gamal, Y. M., Ledford, D. K., Ring, J., Sanchez-Borges, M., Senna, G. E., Sheikh, A., & Thong, B. Y. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.01.038 · Cited by 570
Simons, F. E. R. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.981 · Cited by 368
Coronary Hypersensitivity Disorder: The Kounis Syndrome
Kounis, N. G. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.02.022 · Cited by 341
Metadata
- Authors
- Metcalfe, D. D., & Schwartz, L. B.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 123
- Issue
- 3
- Pages
- 687-688
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2095705376
- Cited by
- 52
- References
- 8
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.